title: Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel.
abstract: BACKGROUND
  Antiplatelet agents are widely recognized for their efficacy in reducing the occurrence of vascular events in patients with atherothrombotic disease. Aspirin is currently considered to be the "reference standard" antiplatelet agent and is recommended by the American Heart Association for use in patients with a wide range of manifestations of cardiovascular disease on the basis of its high benefit-to-risk and benefit-to-cost ratios. Recently, clopidogrel (Plavix, Bristol-Myers Squibb Co), another antiplatelet agent, was approved by the Food and Drug Administration for many of the same indications as aspirin.
  
  
  RESULTS
  Because physicians will be faced with deciding whether to switch from the well-established practice of recommending aspirin for use in patients with atherothrombotic disease, both aspirin and clopidogrel are compared with respect to the primary factors that influence such decisions (ie, their relative efficacy, safety, cost, and convenience of use).
  
  
  CONCLUSIONS
  Based on the available evidence, aspirin is preferred for the majority of stroke or myocardial infarction patients at risk of recurrent atherothrombotic events. Clopidogrel may, however, provide valuable therapeutic benefit over aspirin in patients with peripheral arterial disease and in stroke or myocardial infarction patients for whom aspirin treatment is contraindicated or for whom aspirin fails to achieve the desired therapeutic effect.
authors.affiliation: Center for Stroke Research, Chicago, Ill, USA.
authors.forename: P B
authors.initials: PB
authors.lastname: Gorelick
authors.forename: G V
authors.initials: GV
authors.lastname: Born
authors.forename: R B
authors.initials: RB
authors.lastname: D'Agostino
authors.forename: D F
authors.initials: DF
authors.lastname: Hanley
authors.forename: L
authors.initials: L
authors.lastname: Moye
authors.forename: C J
authors.initials: CJ
authors.lastname: Pepine
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D000077144:Clopidogrel; D003657:Decision Making; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D055502:Secondary Prevention; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin